En poursuivant votre navigation sur ce site, vous acceptez le dépôt de cookies dans votre navigateur. (En savoir plus)
Portail > Offres > Offre UAR3426-CHRGAU-006 - H/F Post doctorat en immunologie

M/W Post-doctorate in Immunology

This offer is available in the following languages:
Français - Anglais

Date Limite Candidature : samedi 4 juin 2022

Assurez-vous que votre profil candidat soit correctement renseigné avant de postuler. Les informations de votre profil complètent celles associées à chaque candidature. Afin d’augmenter votre visibilité sur notre Portail Emploi et ainsi permettre aux recruteurs de consulter votre profil candidat, vous avez la possibilité de déposer votre CV dans notre CVThèque en un clic !

General information

Reference : UAR3426-CHRGAU-006
Date of publication : Saturday, May 14, 2022
Type of Contract : FTC Scientist
Contract Period : 24 months
Expected date of employment : 1 October 2022
Proportion of work : Full time
Remuneration : Gross salary from 3099 € to 3821 € per month depending on experience
Desired level of education : PhD
Experience required : 1 to 4 years


The objective of the research project will be to study the anti-tumor effects of a bispecific antibody coupled to a cytokine (in particular IL-15) capable of activating NK and T lymphocytes in order to increase their cytotoxicity on tumor cells. The techniques employed will combine molecular biology, cell culture, cell sorting, gene transfer in cultures, flow cytometry and immunohistochemical labeling. A good knowledge of the mechanisms of action of cytokines is necessary.


• Plan and carry out experiments to determine the functional consequences of the ex-vivo use of bispecific monoclonal antibodies.
• Process and analyze data, format results for presentation.
• Write reports of experiments or studies, technical notes.
• Proactively participate in the writing of scientific articles.
• Available for professional journeys in the USA and the Cytovia Therapeutics Inc. laboratories in Natick (MA) notably.
• Collaborate with the scientific team in the Natick laboratories in order to coordinate the biological and clinical trials on animals.
• Participate to the CRO selection involved in the preclinical trials (toxicology, PK, PD, biodistribution…).


The used techniques will combine Molecular Biology, cell culture, cell sorting, gene transfers in the cell cultures, flow cytometry and immune-histochemical labeling. A strong knowledge in cytokine action mechanisms is needed including cytokine dosage methods and biological activity determination.

• Knowledge:
- Immunology and Cancerology, NK cells, monoclonal antibodies, health and safety and animal experimentation regulations.
- Protocols on animal models, in particular with NOD SCID and nude mice.
- Knowledge in monoclonal antibodies (mAbs) and their recent formats (ScFv, bispecific Ab, ADC…).
- Clinical knowledge on malignant hemopathies and myelomas notably.
- Cellular cytotoxicity mechanisms related to monoclonal antibodies (ADCC, CDC, ADCP) and apoptosis.
- IPSC (Induced Pluripotent Stem Cells) culture, differentiation and manufacturing applied NK cell and macrophage generation notably.

• Skills and expertise:
- Classic tests for lymphocyte-mediated cytotoxicity.
- Flow cytometry for cell phenotype with monoclonal antibodies, cell sorting and cell proliferation (CFSE) and tumor death (7AAD) assays.
- ELISA and immunofluorecence tests, Kd determination and epitope mapping (Biacore).
- Antibody coupling with proteins and enzymes.

• Abilities:
- Know-how to manage a research project.
- Manage relationships with interlocutors.
- Use activity-specific software.

• English: Written and oral comprehension - Level 2/3 (B1/B2 CEFR sorting) at least. Written and oral expression - Level 2/3 (B1/B2 CEFR sorting) at least.

Work Context

The project aims at studying “The anti-tumor activity of bispecific monoclonal antibodies in hematological malignancies and solid tumours”.

The activity will be partly carried out in the Biocampus structure Baculovirus and Therapy laboratory located in Saint Christol Lès Alès and the company Cytovia Therapeutics located in Cytovia Therapeutics Europe 25-27 Av. du Québec, 91140 Villebon-sur-Yvette.

• BioCampus Montpellier has been created with the objective of structuring and pooling all available cutting-edge technological tools. Currently, BioCampus is composed of 18 facilities and manages the main technological platforms dedicated to Life Science research in the Mediterranean part of the French Occitanie region. The post-doctoral scientist will work in Baculovirus and Therapy team which conducts research in the development of innovative technologies for the production of protein complexes in particular mono- and bispecific antibodies using the baculovirus expression system. This team includes 2 engineers, 2 assistant engineers, 1 technician and all facilities for virology, molecular biology, purification and a white room equipped with bioreactors for recombinant protein production.

• Cytovia Therapeutics Inc. (www.cytoviatx.com). We are an innovative, global biotechnology company focused on harnessing the power of natural killer (NK cells) to fight cancer through multispecific antibodies and stem cell engineering. We are developing novel therapies aimed at addressing solid and hematological tumors with significant unmet medical needs. We seek to combine our gene-edited induced pluripotent stem cell (iPSC derived NK cell) and Flex-NK cell-engager antibody platforms to develop differentiated therapies across multiple indications. Our lead program aims to develop first-in-class hepatocellular carcinoma (HCC) therapies targeting glypican-3 (GPC3). Our novel tri-specific Flex-NK Cell antibody engager binds to NK cells through NKp46 and CD16a while targeting GPC3 expressed on HCC cells. We can augment the power of our NK cell-engager by combining it with either unedited or edited iPSC-derived NK (iNK cells). Our pipeline includes edited iNK cell and chimeric antigen receptor (CAR-iNK), cell candidates directed against GPC3. Our broader pipeline also includes a CD38 targeting Flex-NK cell-engager and a CD38 targeting CAR-iNK cell candidates for the treatment of multiple myeloma (MM) and epidermal growth factor receptor (EGFR), targeting CAR-iNK cells for treatment of glioblastoma multiforme (GBM). We expect to file two INDs in the second half of 2022for CYT-303, our GPC3 Flex-NK cell-engager antibody, and CYT-100, our unedited iNK cells.

Constraints and risks


Additional Information

This recruitment offer is part of the “France Relance” plan on a collaborative research project with a company that will be subject to the validation of DRARI.

We talk about it on Twitter!